Literature DB >> 16970511

Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.

June S Almenoff1, Karol K LaCroix, Nancy A Yuen, David Fram, William DuMouchel.   

Abstract

BACKGROUND AND OBJECTIVES: There is increasing interest in using disproportionality-based signal detection methods to support postmarketing safety surveillance activities. Two commonly used methods, empirical Bayes multi-item gamma Poisson shrinker (MGPS) and proportional reporting ratio (PRR), perform differently with respect to the number and types of signals detected. The goal of this study was to compare and analyse the performance characteristics of these two methods, to understand why they differ and to consider the practical implications of these differences for a large, industry-based pharmacovigilance department.
METHODS: We compared the numbers and types of signals of disproportionate reporting (SDRs) obtained with MGPS and PRR using two postmarketing safety databases and a simulated database. We recorded signal counts and performed a qualitative comparison of the drug-event combinations signalled by the two methods as well as a sensitivity analysis to better understand how the thresholds commonly used for these methods impact their performance.
RESULTS: PRR detected more SDRs than MGPS. We observed that MGPS is less subject to confounding by demographic factors because it employs stratification and is more stable than PRR when report counts are low. Simulation experiments performed using published empirical thresholds demonstrated that PRR detected false-positive signals at a rate of 1.1%, while MGPS did not detect any statistical false positives. In an attempt to separate the effect of choice of signal threshold from more fundamental methodological differences, we performed a series of experiments in which we modified the conventional threshold values for each method so that each method detected the same number of SDRs for the example drugs studied. This analysis, which provided quantitative examples of the relationship between the published thresholds for the two methods, demonstrates that the signalling criterion published for PRR has a higher signalling frequency than that published for MGPS. DISCUSSION AND
CONCLUSION: The performance differences between the PRR and MGPS methods are related to (i) greater confounding by demographic factors with PRR; (ii) a higher tendency of PRR to detect false-positive signals when the number of reports is small; and (iii) the conventional thresholds that have been adapted for each method. PRR tends to be more 'sensitive' and less 'specific' than MGPS. A high-specificity disproportionality method, when used in conjunction with medical triage and investigation of critical medical events, may provide an efficient and robust approach to applying quantitative methods in routine postmarketing pharmacovigilance.

Mesh:

Year:  2006        PMID: 16970511     DOI: 10.2165/00002018-200629100-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  18 in total

1.  A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database.

Authors:  M Lindquist; M Ståhl; A Bate; I R Edwards; R H Meyboom
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

2.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Authors:  S J Evans; P C Waller; S Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

3.  Use of measures of disproportionality in pharmacovigilance: three Dutch examples.

Authors:  Antoine C G Egberts; Ronald H B Meyboom; Eugène P van Puijenbroek
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

4.  Practical pharmacovigilance analysis strategies.

Authors:  A Lawrence Gould
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003 Oct-Nov       Impact factor: 2.890

5.  Trimethoprim-induced hyperkalaemia -- lessons in data mining.

Authors:  Manfred Hauben
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

6.  A challenge to the data miners.

Authors:  David E Lilienfeld
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-12       Impact factor: 2.890

7.  Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance.

Authors:  Emmanuel Roux; Frantz Thiessard; Annie Fourrier; Bernard Bégaud; Pascale Tubert-Bitter
Journal:  IEEE Trans Inf Technol Biomed       Date:  2005-12

8.  The detection of adverse reactions to therapeutic drugs.

Authors:  D J Finney
Journal:  Stat Med       Date:  1982 Apr-Jun       Impact factor: 2.373

9.  Safety related drug-labelling changes: findings from two data mining algorithms.

Authors:  Manfred Hauben; Lester Reich
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated with atypical antipsychotics.

Authors:  Manfred Hauben
Journal:  Pharmacotherapy       Date:  2004-09       Impact factor: 4.705

View more
  28 in total

1.  Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection.

Authors:  Sandra de Bie; Katia M C Verhamme; Sabine M J M Straus; Bruno H Ch Stricker; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

2.  A decade of data mining and still counting.

Authors:  Manfred Hauben; G Niklas Norén
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

3.  Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases.

Authors:  Suzie Seabroke; Gianmario Candore; Kristina Juhlin; Naashika Quarcoo; Antoni Wisniewski; Ramin Arani; Jeffery Painter; Philip Tregunno; G Niklas Norén; Jim Slattery
Journal:  Drug Saf       Date:  2016-04       Impact factor: 5.606

4.  Innovations for the future of pharmacovigilance.

Authors:  June S Almenoff
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

5.  Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS).

Authors:  Emily Jane Woo; Robert Ball; Dale R Burwen; M Miles Braun
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  Early detection of pharmacovigilance signals with automated methods based on false discovery rates: a comparative study.

Authors:  Ismaïl Ahmed; Frantz Thiessard; Ghada Miremont-Salamé; Françoise Haramburu; Carmen Kreft-Jais; Bernard Bégaud; Pascale Tubert-Bitter
Journal:  Drug Saf       Date:  2012-06-01       Impact factor: 5.606

7.  Choosing thresholds for statistical signal detection with the proportional reporting ratio.

Authors:  Jim Slattery; Yolanda Alvarez; Ana Hidalgo
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

8.  Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.

Authors:  Steven Bailey; Ajay Singh; Robert Azadian; Peter Huber; Michael Blum
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

9.  More eyeballs on AERS.

Authors:  Leslie A Pratt; Paul N Danese
Journal:  Nat Biotechnol       Date:  2009-07       Impact factor: 54.908

10.  Impact of stratification on adverse drug reaction surveillance.

Authors:  Johan Hopstadius; G Niklas Norén; Andrew Bate; I Ralph Edwards
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.